Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis

Open access

Abstract

A novel resource centre for TP53 mutations and mutants has been developed (http://p53.fr). TP53 gene dysfunction can be found in the majority of human cancer types. The potential use of TP53 mutation as a biomarker for clinical studies or exposome analysis has led to the publication of thousands of reports describing the TP53 gene status in >10,000 tumours. The UMD TP53 mutation database was created in 1990 and has been regularly updated. The 2012 release of the database has been carefully curated, and all suspicious reports have been eliminated. It is available either as a flat file that can be easily manipulated or as novel multi-platform analytical software that has been designed to analyse various aspects of TP53 mutations. Several tools to ascertain TP53 mutations are also available for download. We have developed TP53MULTLoad, a manually curated database providing comprehensive details on the properties of 2549 missense TP53 mutants. More than 100,000 entries have been arranged in 39 different activity fields, such as change of transactivation on various promoters, apoptosis or growth arrest. For several hot spot mutants, multiple gain of function activities are also included. The database can be easily browsed via a graphical user interface.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gks1033

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Trends in TP53 mutation publications. (A) Number of mutations published each year using either Sanger methodology (Red) or NGS (blue). For 2012 (last column on the left), only the first 6 months of the year were taken into account. Only publications describing molecular analysis of TP53 mutations were included in this analysis. (B) Number of novel TP53 mutants described each year since the first discovery.
Figure 1. Trends in TP53 mutation publications. (A) Number of mutations published each year using either Sanger methodology (Red) or NGS (blue). For 2012 (last column on the left), only the first 6 months of the year were taken into account. Only publications describing molecular analysis of TP53 mutations were included in this analysis. (B) Number of novel TP53 mutants described each year since the first discovery.CC BY-NC · PubMed Central
Figure 2. Summary of the content of the latest version of the TP53 mutation database. Mutants and mutations have been classified into three categories (missense, frameshift and nonsense). The features of the 15 most frequent mutations in the database are shown in the right part of the figure.
Figure 2. Summary of the content of the latest version of the TP53 mutation database. Mutants and mutations have been classified into three categories (missense, frameshift and nonsense). The features of the 15 most frequent mutations in the database are shown in the right part of the figure.CC BY-NC · PubMed Central
Figure 3. An overview of the various features of TP53_DBM_INVEST. (A) Distribution of mutational events; (B) List and description of hot spot mutations; (C) Distribution of tandem mutations; (D) Frequency of TP53 mutations in various regions of the TP53 gene; (E) Summary of the strategy used for the analysis of TP53 mutations (top panel: number of studies focusing on sequencing of different TP53 gene regions; bottom panel: number of studies adopting specific experimental approaches); (F) Frequency of TP53 mutations at dipyrimidine sites for specific cancer types; (G) Overall distribution of TP53 mutations in the protein.
Figure 3. An overview of the various features of TP53_DBM_INVEST. (A) Distribution of mutational events; (B) List and description of hot spot mutations; (C) Distribution of tandem mutations; (D) Frequency of TP53 mutations in various regions of the TP53 gene; (E) Summary of the strategy used for the analysis of TP53 mutations (top panel: number of studies focusing on sequencing of different TP53 gene regions; bottom panel: number of studies adopting specific experimental approaches); (F) Frequency of TP53 mutations at dipyrimidine sites for specific cancer types; (G) Overall distribution of TP53 mutations in the protein.CC BY-NC · PubMed Central
Figure 4. Biological activity report for the hotspot mutant R175H. (A) Downloadable table view listing results from different assays, systems and experimental approaches. (B) Graphical summary of DNA binding and transactivation results. (C) Example of the hyperlink to the publications curated in this section of the database.
Figure 4. Biological activity report for the hotspot mutant R175H. (A) Downloadable table view listing results from different assays, systems and experimental approaches. (B) Graphical summary of DNA binding and transactivation results. (C) Example of the hyperlink to the publications curated in this section of the database.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 185

Metadata

Authors
Leroy, B., Fournier, J. L., Ishioka, C., Monti, P., Inga, A., Fronza, G., & Soussi, T.
Affiliations
  • Université Pierre-et-Marie-Curie (FR)
  • Tohoku University (JP)
  • Ospedale Policlinico San Martino (IT)
  • University of Trento (IT)
  • Karolinska Institutet (SE)
Corresponding author
Soussi, Thierry
Venue
Nucleic Acids Research
Published
2012-11-17
Volume
41
Issue
D1
Pages
D962-D969
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W2041908101
Cited by
185
References
39
Citations by year
2026: 11 · 2025: 13 · 2024: 10 · 2023: 6 · 2022: 19 · 2021: 14 · 2020: 18 · 2019: 15 · 2018: 18 · 2017: 18 · 2016: 15 · 2015: 9 · 2014: 15 · 2013: 3 · 2012: 1
FWCI
4.43
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
Funders
  • Cancerfonden
  • Vetenskapsrådet
  • Associazione Italiana per la Ricerca sul Cancro (IG#5506)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
TP53, TP53 mutation, missense mutants, gain-of-function, transcriptional activation, apoptosis, tumour biomarkers, cancer genomics, database curation
MeSH terms
Humans, Mutation, Neoplasms, Genes, p53, Tumor Suppressor Protein p53, Internet, Databases, Nucleic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. https://app.cochat.ai/papers/10.1093/nar/gks1033
The paper
Leroy, B., Fournier, J. L., Ishioka, C., Monti, P., Inga, A., Fronza, G., & Soussi, T. (2013). The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Research. https://doi.org/10.1093/nar/gks1033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.